CRB-65

Mortality risk and treatment setting in community-acquired pneumonia — no blood test needed

Sources last checked: 2026-10-13

CRB-65

Mortality risk and treatment setting in community-acquired pneumonia — no blood test needed

0
0 — low risk

30-day mortality 0 % in the German CAPNETZ cohort (2 % in hospitalised patients, German quality-assurance data). AWMF S3 2021 provides for outpatient treatment if the patient is clinically stable, SpO₂ > 92 % without new desaturation, with no unstable comorbidity, no complication and no social reason for admission, with re-evaluation after 48–72 h.

A low score never overrides the bedside picture: hypoxaemia (SpO₂ ≤ 92 %), unstable comorbidity, complications such as pleural effusion or social factors can require admission at CRB-65 = 0. It discriminates poorly in nursing-home residents and bedbound patients.

Source: Bauer TT, Ewig S, Marre R, Suttorp N, Welte T; CAPNETZ Study Group. CRB-65 predicts death from community-acquired pneumonia. J Intern Med 2006;260(1):93-101.Open

Interpretation

0 — low risk30-day mortality 0 % in the German CAPNETZ cohort (2 % in hospitalised patients, German quality-assurance data). AWMF S3 2021 provides for outpatient treatment if the patient is clinically stable, SpO₂ > 92 % without new desaturation, with no unstable comorbidity, no complication and no social reason for admission, with re-evaluation after 48–72 h.
1–2 — increased riskMortality ≈ 6 % (CAPNETZ) to 13 % (hospitalised patients). AWMF S3 2021 no longer regards outpatient treatment as the default in this group; the guideline provides for an assessment of hospital admission that includes oxygenation and comorbidities.
3–4 — high riskMortality ≈ 23 % (CAPNETZ) to 34 % (hospitalised patients). AWMF S3 2021 provides for hospital admission in this group, with prompt assessment for organ dysfunction, sepsis and the need for intensive care.

What is the CRB-65?

CRB-65 estimates the 30-day mortality of community-acquired pneumonia from four bedside findings: confusion, respiratory rate, blood pressure and age. It is CURB-65 (Lim, Thorax 2003) without the urea value, and was validated for both outpatients and inpatients in the German CAPNETZ network (Bauer, J Intern Med 2006). The German AWMF S3 guideline 2021 uses it as the objective aid for deciding on outpatient versus hospital treatment.

When to use it

  • Adults with clinically or radiologically diagnosed community-acquired pneumonia in general practice or the emergency department.
  • Deciding, together with oxygenation and comorbidities, whether outpatient treatment is safe.
  • Where no blood test is available — the main advantage over CURB-65.
  • Re-assessing patients whose condition changes in the first days of treatment.

When not to use it

  • Hospital-acquired or ventilator-associated pneumonia, or severely immunosuppressed patients.
  • Nursing-home residents or chronically bedbound patients, in whom the score no longer identifies a low-risk group.
  • As the only criterion for intensive care — ATS/IDSA minor/major criteria and sepsis assessment address that question.

How it is calculated

CriterionPoints
Confusion (new disorientation to person, place or time)+1
Respiratory rate ≥ 30 /min+1
Systolic BP < 90 mmHg or diastolic BP ≤ 60 mmHg+1
Age ≥ 65 years+1

Clinical pearls and limitations

  • A low score never overrides the bedside picture: hypoxaemia (SpO₂ ≤ 92 %), unstable comorbidity, complications such as pleural effusion or social factors can require admission at CRB-65 = 0. It discriminates poorly in nursing-home residents and bedbound patients.
  • AWMF S3 2021: CRB-65 = 0 supports outpatient care only together with SpO₂ > 92 %, no unstable comorbidity, no complication and adequate home support.
  • The AWMF S3 guideline includes oxygenation in the assessment of every patient — pulse oximetry in practice, blood gas in the ED. Hypoxaemia was the commonest reason for admission despite a low score.
  • Confusion means new disorientation, not known dementia.
  • AWMF S3 2021 provides for re-evaluation after 48–72 hours, the window in which deterioration typically occurs.
  • Systolic < 90 OR diastolic ≤ 60 mmHg — either one scores the point.

Frequently asked questions

What is the difference between CRB-65 and CURB-65?

CURB-65 adds one point for urea > 7 mmol/L. CRB-65 drops the lab value so it can be used in general practice; prognostic accuracy is comparable in German data.

Can a patient with CRB-65 = 0 always go home?

No. The German guideline also requires adequate oxygenation (SpO₂ > 92 %), no unstable comorbidity, no complication such as pleural effusion and no social reason for admission.

What mortality does a CRB-65 of 1–2 mean?

About 6 % in the CAPNETZ study population and about 13 % among hospitalised patients in German quality-assurance data.

Does age ≥ 65 alone justify admission?

Not on its own. The guideline asks for age to be judged together with comorbidity, functional status and the social situation.

Evidence and guidelines

  1. Primary source: Bauer TT, Ewig S, Marre R, Suttorp N, Welte T; CAPNETZ Study Group. CRB-65 predicts death from community-acquired pneumonia. J Intern Med 2006;260(1):93-101.
  2. Ewig S, Kolditz M, Pletz M et al. S3-Leitlinie Behandlung von erwachsenen Patienten mit ambulant erworbener Pneumonie – Update 2021. AWMF-Register 020-020 (DGP, PEG, DGI, DGIIN, DEGAM, ÖGP, SGP u. a.).
  3. Lim WS et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58(5):377-382.

Have a follow-up question?

Medelix answers clinical questions from current guidelines and studies — every statement with its source.

Ask Medelix about the CRB-65

Related calculators

Embed this calculatorFree to use on your website, intranet or teaching page. Copy the code below.
<iframe src="https://medelix.ai/en/embed/crb-65" title="CRB-65 – Medelix" width="100%" height="620" style="border:0;max-width:720px" loading="lazy"></iframe> <p><a href="https://medelix.ai/en/calculators/crb-65">CRB-65 calculator by Medelix</a></p>

For healthcare professionals and medical students. These tools support, and do not replace, clinical judgement. Always check results against the original source and your local protocols.